Literature DB >> 26423405

Tissue expression levels of miR-29b and miR-422a in children, adolescents, and young adults' age groups and their association with prediction of poor prognosis in human osteosarcoma.

Reza Bahador1, Afshin Taheriazam2, Alireza Mirghasemi3, Ali Torkaman4, Mohammadreza Shakeri1, Emad Yahaghi5, Peyman Karimi Goudarzi6.   

Abstract

Osteosarcoma is the most common type of bone cancer in children and adolescents. MicroRNAs (miRNAs) play important roles in the development, differentiation, and function of different cell types and in the pathogenesis of various human diseases. miRNAs are differentially expressed in normal and cancer cells. The investigation of miRNA expression between healthy subjects and patients with osteosarcoma is crucial for future clinical trials. In this study, the expression levels of miRNAs were detected by qRT-PCR. Correlation between expression levels of tow miRNAs and different clinicopathological characteristics were analyzed using the χ (2) test. Survival rate was detected using the log-rank test and Kaplan-Meier method. qRT-PCR was shown that expression levels of miR-29b and miR-422a were strongly decreased in osteosarcoma bone tissue compared with noncancerous bone tissues. Our result indicated that the low expression levels of miR-29b and miR-422a showed strong correlation with large tumor size (P = 0.20; 0.029), advanced TNM stage (P = 0.001; 0.012), distant metastasis (P = 0.008; 0.019), and grade of tumor (P = 0.009; 0.016). Kaplan-Meier survival analysis showed that the low expressions of miR-29b/miR-422a were correlated with shorter time overall survival (log-rank test, P = 0.009; P = 0.013). Moreover, multivariate Cox proportional hazards model indicated that miR-29b and miR-422a (P = 0.024; P = 0.016) were independent prognostic markers of overall survival of patients. Our result indicated that downregulation of miR-29b and miR-422a may be linked to the prediction of poor prognosis, indicating that miR-29b and miR-422a may be a valuable prognostic marker for osteosarcoma patients.

Entities:  

Keywords:  Osteosarcoma; PCR; Pathology; Survival; miR-29b and miR-422a

Year:  2015        PMID: 26423405     DOI: 10.1007/s13277-015-4140-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  20 in total

1.  Skip metastases in osteosarcoma: experience of the Cooperative Osteosarcoma Study Group.

Authors:  Leo Kager; Andreas Zoubek; Ulrike Kastner; Beate Kempf-Bielack; Jenny Potratz; Rainer Kotz; G Ulrich Exner; Christiane Franzius; Susanna Lang; Rainer Maas; Heribert Jürgens; Helmut Gadner; Stefan Bielack
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

2.  Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience.

Authors:  Sarah E S Leary; Amy W Wozniak; Catherine A Billups; Jianrong Wu; Valerie McPherson; Michael D Neel; Bhaskar N Rao; Najat C Daw
Journal:  Cancer       Date:  2013-04-26       Impact factor: 6.860

3.  MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma.

Authors:  Daniel Baumhoer; Stephanie Zillmer; Kristian Unger; Michael Rosemann; Michael J Atkinson; Martin Irmler; Johannes Beckers; Heide Siggelkow; Irene von Luettichau; Gernot Jundt; Jan Smida; Michaela Nathrath
Journal:  Cancer Genet       Date:  2012-05

4.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

5.  Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA.

Authors:  N Dai; Z Y Zhong; Y P Cun; Y Qing; Ch Chen; P Jiang; M X Li; D Wang
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

6.  Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29.

Authors:  Monika Kwiecinski; Natalia Elfimova; Andrea Noetel; Ulrich Töx; Hans-Michael Steffen; Ulrich Hacker; Roswitha Nischt; Hans Peter Dienes; Margarete Odenthal
Journal:  Lab Invest       Date:  2012-05-07       Impact factor: 5.662

7.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

8.  MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma.

Authors:  Guangyi Zhao; Chengkui Cai; Tongtao Yang; Xiuchun Qiu; Bo Liao; Wei Li; Zhenwei Ji; Jian Zhao; Haien Zhao; Mingjun Guo; Qiong Ma; Chun Xiao; Qingyu Fan; Baoan Ma
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

9.  Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer.

Authors:  Rupninder Sandhu; Ashley G Rivenbark; Randi M Mackler; Chad A Livasy; William B Coleman
Journal:  Int J Oncol       Date:  2013-11-29       Impact factor: 5.650

Review 10.  The role of miR-29b in cancer: regulation, function, and signaling.

Authors:  Bin Yan; Qiong Guo; Fa-Jun Fu; Zhao Wang; Zhuo Yin; Yong-Bao Wei; Jin-Rui Yang
Journal:  Onco Targets Ther       Date:  2015-03-03       Impact factor: 4.147

View more
  12 in total

1.  MiR-422a weakened breast cancer stem cells properties by targeting PLP2.

Authors:  Yanmei Zou; Yuandong Chen; Shuo Yao; Guangrui Deng; Dian Liu; Xun Yuan; Shunfang Liu; Jie Rao; Huihua Xiong; Xianglin Yuan; Shiying Yu; Feng Zhu; Yihua Wang; Hua Xiong
Journal:  Cancer Biol Ther       Date:  2018-03-30       Impact factor: 4.742

2.  MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma.

Authors:  Nathalie Bonnin; Emma Armandy; Julien Carras; Sylvain Ferrandon; Priscillia Battiston-Montagne; Marc Aubry; Sébastien Guihard; David Meyronet; Jean-Philippe Foy; Pierre Saintigny; Sonia Ledrappier; Alain Jung; Ruth Rimokh; Claire Rodriguez-Lafrasse; Delphine Poncet
Journal:  Oncotarget       Date:  2016-07-12

3.  miR-1 Inhibits Cell Growth, Migration, and Invasion by Targeting VEGFA in Osteosarcoma Cells.

Authors:  Junjie Niu; Yibao Sun; Qiaoge Guo; Dongju Niu; Bo Liu
Journal:  Dis Markers       Date:  2016-09-29       Impact factor: 3.434

4.  miR-486-3p, miR-139-5p, and miR-21 as Biomarkers for the Detection of Oral Tongue Squamous Cell Carcinoma.

Authors:  Zujian Chen; Tianwei Yu; Robert J Cabay; Yi Jin; Ishrat Mahjabeen; Xianghong Luan; Lei Huang; Yang Dai; Xiaofeng Zhou
Journal:  Biomark Cancer       Date:  2017-01-09

Review 5.  Circulating microRNA-422a is associated with lymphatic metastasis in lung cancer.

Authors:  Lina Wu; Bo Hu; Bingtian Zhao; Yinan Liu; Yue Yang; Lijian Zhang; Jinfeng Chen
Journal:  Oncotarget       Date:  2017-06-27

6.  Identification of critical genes associated with human osteosarcoma metastasis based on integrated gene expression profiling.

Authors:  Hongwu Fan; Shan Lu; Shengqun Wang; Shanyong Zhang
Journal:  Mol Med Rep       Date:  2019-06-03       Impact factor: 2.952

7.  Novel miR-29b target regulation patterns are revealed in two different cell lines.

Authors:  Wenting Zhao; Lesley Cheng; Camelia Quek; Shayne A Bellingham; Andrew F Hill
Journal:  Sci Rep       Date:  2019-11-25       Impact factor: 4.379

8.  Meta-analysis of the differentially expressed microRNA profiles in nasopharyngeal carcinoma.

Authors:  Junwen Luan; Junfu Wang; Qinghong Su; Xuemei Chen; Guosheng Jiang; Xiaoqun Xu
Journal:  Oncotarget       Date:  2016-03-01

9.  Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway.

Authors:  Jiaguo Liu; Bin Luo; Meng Zhao
Journal:  Mol Med Rep       Date:  2017-09-28       Impact factor: 2.952

10.  miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1.

Authors:  Wen-Ting Wei; Xin-Xin Nian; Shu-Yang Wang; Hong-Li Jiao; Yong-Xia Wang; Zhi-Yuan Xiao; Run-Wei Yang; Yan-Qing Ding; Ya-Ping Ye; Wen-Ting Liao
Journal:  Cancer Cell Int       Date:  2017-10-28       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.